Boothbay Fund Management’s United Therapeutics UTHR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-782
Closed -$424K – 2510
2026
Q2
$424K Buy
+782
New +$440K 0.01% 1599
2025
Q4
– Sell
-3,000
Closed -$1.26M – 2393
2025
Q3
$1.26M Buy
+3,000
New +$1.01M 0.02% 742
2024
Q4
– Sell
-810
Closed -$290K – 1926
2024
Q3
$290K Buy
+810
New +$274K 0.01% 1269
2022
Q3
– Sell
-5,104
Closed -$1.2M – 2612
2022
Q2
$1.2M Buy
+5,104
New +$1.04M 0.03% 738
2021
Q4
– Sell
-6,549
Closed -$1.21M – 2244
2021
Q3
$1.21M Sell
6,549
-1,240
-16% -$244K 0.03% 670
2021
Q2
$1.4M Sell
7,789
-1,658
-18% -$316K 0.04% 548
2021
Q1
$1.58M Buy
9,447
+7,638
+422% +$1.27M 0.06% 407
2020
Q4
$275K Buy
+1,809
New +$237K 0.01% 986
2017
Q2
– Sell
-2,080
Closed -$282K – 848
2017
Q1
$282K Buy
+2,080
New +$315K 0.05% 454

Other funds holding UTHR

Boothbay Fund Management's UTHR Position: Q3 2026 in Review

Boothbay Fund Management sold out of United Therapeutics (UTHR) in Q3 2026, closing a stake of 782 shares — an estimated $424K sold.

Boothbay Fund Management first reported a position in UTHR in Q1 2017 and held it in 9 quarters. The position peaked at $1.58M in Q1 2021. 846 funds tracked by Wall St. Rank hold UTHR as of Q3 2026.

  • Boothbay Fund Management reported no remaining United Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Boothbay Fund Management sold 782 United Therapeutics shares in Q3 2026, an estimated $424K.
  • Boothbay Fund Management first reported a position in United Therapeutics in Q1 2017 and held it in 9 quarters.
  • Boothbay Fund Management's United Therapeutics position peaked at $1.58M in Q1 2021.
  • 846 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2026.

Based on Boothbay Fund Management's 13F filing for Q3 2026, filed 16 Nov 2026.